MBX BIOSCIENCES INC (MBX) Fundamental Analysis & Valuation

NASDAQ:MBX • US55287L1017

Current stock price

28.89 USD
+0.21 (+0.73%)
Last:

This MBX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MBX Profitability Analysis

1.1 Basic Checks

  • MBX had negative earnings in the past year.
  • MBX had a negative operating cash flow in the past year.
MBX Yearly Net Income VS EBIT VS OCF VS FCFMBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -20M -40M -60M -80M

1.2 Ratios

  • MBX's Return On Assets of -22.58% is in line compared to the rest of the industry. MBX outperforms 58.55% of its industry peers.
  • MBX has a Return On Equity of -23.56%. This is in the better half of the industry: MBX outperforms 66.32% of its industry peers.
Industry RankSector Rank
ROA -22.58%
ROE -23.56%
ROIC N/A
ROA(3y)-28.11%
ROA(5y)N/A
ROE(3y)-29.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBX Yearly ROA, ROE, ROICMBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • MBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBX Yearly Profit, Operating, Gross MarginsMBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MBX Health Analysis

2.1 Basic Checks

  • MBX has more shares outstanding than it did 1 year ago.
  • MBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBX Yearly Shares OutstandingMBX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M
MBX Yearly Total Debt VS Total AssetsMBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • MBX has an Altman-Z score of 50.83. This indicates that MBX is financially healthy and has little risk of bankruptcy at the moment.
  • MBX has a better Altman-Z score (50.83) than 95.85% of its industry peers.
  • There is no outstanding debt for MBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 50.83
ROIC/WACCN/A
WACCN/A
MBX Yearly LT Debt VS Equity VS FCFMBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 24.62 indicates that MBX has no problem at all paying its short term obligations.
  • The Current ratio of MBX (24.62) is better than 94.82% of its industry peers.
  • MBX has a Quick Ratio of 24.62. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 24.62, MBX belongs to the top of the industry, outperforming 94.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 24.62
Quick Ratio 24.62
MBX Yearly Current Assets VS Current LiabilitesMBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MBX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.57% over the past year.
EPS 1Y (TTM)16.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • MBX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.50% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.24%
EPS Next 2Y-26.14%
EPS Next 3Y-12.46%
EPS Next 5Y11.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBX Yearly Revenue VS EstimatesMBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B
MBX Yearly EPS VS EstimatesMBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MBX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBX Price Earnings VS Forward Price EarningsMBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBX Per share dataMBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • MBX's earnings are expected to decrease with -12.46% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.14%
EPS Next 3Y-12.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MBX Dividend Analysis

5.1 Amount

  • MBX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MBX Fundamentals: All Metrics, Ratios and Statistics

MBX BIOSCIENCES INC

NASDAQ:MBX (3/23/2026, 10:00:06 AM)

28.89

+0.21 (+0.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners84.55%
Inst Owner Change-0.9%
Ins Owners2.94%
Ins Owner Change2.55%
Market Cap1.37B
Revenue(TTM)N/A
Net Income(TTM)-86.97M
Analysts82.67
Price Target62.32 (115.71%)
Short Float %7.2%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.24%
Min EPS beat(2)10.09%
Max EPS beat(2)20.39%
EPS beat(4)4
Avg EPS beat(4)15.9%
Min EPS beat(4)8.71%
Max EPS beat(4)24.42%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.22%
EPS NQ rev (1m)19.38%
EPS NQ rev (3m)21.28%
EPS NY rev (1m)0%
EPS NY rev (3m)1.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)-2.41
EYN/A
EPS(NY)-3.02
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS7.77
TBVpS7.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.58%
ROE -23.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.11%
ROA(5y)N/A
ROE(3y)-29.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 777.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.62
Quick Ratio 24.62
Altman-Z 50.83
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)406.06%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.26%
EPS Next Y-25.24%
EPS Next 2Y-26.14%
EPS Next 3Y-12.46%
EPS Next 5Y11.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.12%
EBIT Next 3Y-11.19%
EBIT Next 5Y-2.74%
FCF growth 1Y-47.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.21%
OCF growth 3YN/A
OCF growth 5YN/A

MBX BIOSCIENCES INC / MBX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBX.


What is the valuation status of MBX BIOSCIENCES INC (MBX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MBX BIOSCIENCES INC (MBX). This can be considered as Overvalued.


What is the profitability of MBX stock?

MBX BIOSCIENCES INC (MBX) has a profitability rating of 1 / 10.